|
|
||||||||
Viewpoint |
1 The Molecular Biology Institute, University of California, Los Angeles, CA 90095-1752, USA, and
2 Department of Immunology and
3 Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
SUMMARY
Two publications by Mecklenbräuker et al. and Miyamoto et al. describe an essential role for protein kinase C
(PKC
) in the development of immune tolerance, and suggest that PKC
also participates in mechanisms that prevent autoimmunity. Su, Guo, and Rawlings discuss these observations within the larger context of determining specific functions for individual isoforms of PKC in B and T lymphocytes, and the careful control these proteins exert in maintaining proper lymphocyte activation and tolerance.
This article has been cited by other articles:
![]() |
F. Morschhauser, J. F. Seymour, H. C. Kluin-Nelemans, A. Grigg, M. Wolf, M. Pfreundschuh, H. Tilly, J. Raemaekers, M. B. van 't Veer, N. Milpied, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma Ann. Onc., February 1, 2008; 19(2): 247 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Corsini, M. Racchi, E. Sinforiani, L. Lucchi, B. Viviani, G. E. Rovati, S. Govoni, C. L. Galli, and M. Marinovich Age-related decline in RACK-1 expression in human leukocytes is correlated to plasma levels of dehydroepiandrosterone J. Leukoc. Biol., February 1, 2005; 77(2): 247 - 256. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |